Home>First applications of medical instruments in Lecheng
Hainan General Hospital Lecheng Branch makes China's first XOSPATA prescription
Hainan General Hospital Lecheng Branch made China's first XOSPATA prescription on Nov 2, 2020. XOSPATA is the first drug of its kind to be used by Lecheng to treat a patient with acute myelogenous leukemia (AML).
The licensed drug XOSPATA is a global innovative drug introduced for domestic AML patients. It is a second-generation FLT3 inhibitor. Compared with the first-generation drug, it has a better activation structure and specifically binds to FLT3-ITD antibodies, effectively inhibiting the proliferation of leukemia cells, thereby exerting an anti-tumor effect.